Detoxification mechanisms can play a pivotal role in determining tumor cell responses to platinum-based chemotherapy. Glutathione S-transferase-pi (GSTP1) belongs to a supergene family of detoxifying enzymes involved in the prevention of DNA damage and subsequent platinum resistance in numerous cancers. The role of GSTP1 in gastric cancer sensitivity to chemotherapy is, however, not known. In this study, we found that the human gastric cancer cell line MGC803 was significantly more sensitive to cis-platinum (CDDP) than the other gastric cancer lines examined (BGC823 and SGC7901). To explore the potential role of GSTP1 in drug resistance, we measured GSTP1 expression in these cells. GSTP1 mRNA and protein were not detectable in MGC803 cells; both were present in BGC823 and SGC7901 cells. GSTP1 CpG island DNA methylation was examined. We report that promoter hypermethylation was associated with the absence of GSTP1 expression in MGC803 cells. Treatment of these cells with 5-aza-2 0 -deoxycytidine, a DNA methyltransferase inhibitor, restored GSTP1 expression and suppressed sensitivity to CDDP. The selective mitogen-activated protein kinase/extracellular regulated kinase (ERK) pathway inhibitor PD98059 decreased GSTP1 expression in 5-aza-2 0 -deoxycytidine-treated cells. A similar decrease was observed in the BGC823 and SGC7901 cell lines, suggesting that mitogen-activated protein kinase/ERK signaling stimulates GSTP1 expression. CDDP sensitivity was also enhanced by PD98059. These observations indicate that somatic promoter hypermethylation and impaired ERK signaling are associated with decreased GSTP1 expression and CDDP sensitivity in gastric cancer cell lines. Evaluation of promoter methylation and ERK activity may be useful for predicting tumor sensitivity to platinum-based chemotherapeutics.
GSTP1 determines cis-platinum cytotoxicity in gastric adenocarcinoma MGC803 cells: regulation by promoter methylation and extracellular regulated kinase signaling Detoxification mechanisms can play a pivotal role in determining tumor cell responses to platinum-based chemotherapy. Glutathione S-transferase-pi (GSTP1) belongs to a supergene family of detoxifying enzymes involved in the prevention of DNA damage and subsequent platinum resistance in numerous cancers. The role of GSTP1 in gastric cancer sensitivity to chemotherapy is, however, not known. In this study, we found that the human gastric cancer cell line MGC803 was significantly more sensitive to cis-platinum (CDDP) than the other gastric cancer lines examined (BGC823 and SGC7901). To explore the potential role of GSTP1 in drug resistance, we measured GSTP1 expression in these cells. GSTP1 mRNA and protein were not detectable in MGC803 cells; both were present in BGC823 and SGC7901 cells. GSTP1 CpG island DNA methylation was examined. We report that promoter hypermethylation was associated with the absence of GSTP1 expression in MGC803 cells. Treatment of these cells with 5-aza-2 0 -deoxycytidine, a DNA methyltransferase inhibitor, restored GSTP1 expression and suppressed sensitivity to CDDP. The selective mitogen-activated protein kinase/extracellular regulated kinase (ERK) pathway inhibitor PD98059 decreased GSTP1 expression in 5-aza-2 0 -deoxycytidine-treated cells. A similar decrease was observed in the BGC823 and SGC7901 cell lines, suggesting that mitogen-activated protein kinase/ERK signaling stimulates GSTP1 expression. CDDP sensitivity was also enhanced by PD98059. These observations indicate that somatic promoter hypermethylation and impaired ERK signaling are associated with decreased GSTP1 expression and CDDP sensitivity in gastric cancer cell lines. Evaluation of promoter methylation and ERK activity may be useful for predicting tumor sensitivity to platinum-based chemotherapeutics. 
Introduction
Gastric cancer is one of the most common malignancies worldwide. Global estimates in the year 2008 reveal that the incidence of gastric cancer is very high in East Asia, and particularly in China (36/100 000) [1] . Numerous therapies for advanced gastric cancer have been explored, including different chemotherapeutic modalities, and these have significantly prolonged survival. Drug resistance is, however, a major problem that limits the effectiveness of chemotherapies used to treat gastric cancer.
Cisplatin (cis-platinum, CDDP) is among the most widely used and broadly active cytotoxic anticancer drugs. Treatment leads to the intracellular formation of highly reactive platinum complexes. These inhibit DNA synthesis through covalent binding to DNA molecules, forming intrastrand and interstrand DNA cross-links.
Earlier study has evaluated candidate predictive markers for responses to platinum-based chemotherapy including Na + /K + -ATPase, multidrug resistance protein 1, the glutathione S-transferase (GST) family, excision repair cross-complementing 1 and 2, and p53 [2] [3] [4] [5] . The multifunctional detoxifying GST enzymes have been specifically implicated in the metabolism of platinum drugs [6] . Glutathione S-transferase-pi (GSTP1) is an important member of the GST family and detoxifies electrophilic carcinogens by catalyzing their conjugation to glutathione. Cells with higher levels of GSTP1 would thus be expected to be more resistant to platinum-based chemotherapy. Conversely, lower detoxification capacity might be associated with drug sensitivity. Singal et al. [7] reported that high GSTP1 levels are associated with poor prognosis in prostate cancer. We reported previously that GSTP1 is widely overexpressed in different gastric cancer classes ranging from dysplasia to advanced carcinoma [8, 9] . Similar results have been reported in other recent studies [10, 11] . There has therefore been considerable clinical interest in evaluating GSTP1 as a candidate predictive marker for platinum-based chemotherapy of gastric cancers [12] .
Earlier study has shown that GSTP1 expression is regulated at the transcriptional level [13] . Hypermethylation of the promoter region is often associated with loss of GSTP1 expression, this phenomenon has been observed in solid tumors [14] [15] [16] . GST gene expression is also responsive to extracellular stimuli and in HepG2 cells is coordinately regulated by transcription factors [17] . The mitogenactivated protein kinase (MAPK)/extracellular regulated kinase (ERK) signaling pathway plays a central role in transcription activation. It was recently shown that MAPK/ ERK signaling could promote resistance to platinum-based compounds in both lung cancer [18] [19] [20] and ovarian cancer [21, 22] . However, it remains unknown whether the MAPK/ ERK pathway regulates GSTP1 gene expression and platinum resistance in gastric cancer.
In this study, we first investigated a potential association between gene methylation and GSTP1 enzyme expression in gastric cancer cell lines. We also investigated the role of MAPK/ERK signaling in GSTP1 expression. Finally, we examined whether GSTP1 expression modulates chemotherapeutic sensitivity to CDDP.
Materials and methods

Reagents and antibodies
3-(4,5-Dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), dimethyl sulfoxide, and 5-aza-2 0 -deoxycytidine (5-aza-dC) were purchased from Sigma (St. Louis, Missouri, USA). The specific ERK1/2 inhibitor PD98059 was purchased from Promega (Madison, Wisconsin, USA). Anti-ERK1/2 and phospho-ERK1/2 were purchased from Cell Signal Technology (Danvers, Massachusetts, USA). Anti-GST-P1 and anti-tubulin monoclonal antibodies were from Santa Cruz Biotechnology (Santa Cruz, California, USA).
Cells and cell culture
The human gastric cancer cell lines MGC803, BGC823, and SGC7901 were cultured in RPMI1640 medium (Gibco BRL, Grand Ysland, New York, USA) supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, and 100 U/ml streptomycin at 371C in a humidified atmosphere containing 5% CO 2 . Culture media were changed every 2-4 days.
Cell viability assay
Cell viability was determined using the MTT-uptake colorimetric assay. Cells were seeded at 2 Â 10 3 cells/well in 96-well plates and incubated in culture medium overnight. Separate experimental groups were treated with different concentrations of anticancer agents, including CDDP, 5-fluorouracil, epirubicin, or paclitaxel. Cells were treated with 10 mmol/l 5-aza-dC (72 h) before the addition of anticancer agents (or saline in controls) and incubation for a further 48 h. Twenty microliters of MTT solution (5 mg/ml) was added to each well and incubation was continued for 4 h at 371C. The cell culture medium was removed, cells were lysed in 150 ml of dimethylsulfoxide, and the optical density (OD) was measured at 570 nm using a microplate reader (Bio-Rad, Hercules, California, USA). The following formula was used: cell viability = (OD of the experimental sample/ OD of the control group) Â 100%.
RNA extraction, reverse transcription, and amplification
Cell lines MGC803, BGC823, and SGC7901 were collected and washed twice with ice-cold phosphatebuffered saline and total RNA extracted with the RNeasy mini kit (Qiagen, Carlsbad, California, USA) as described by the manufacturer. RNA was reverse transcribed as follows. One microgram of RNA was mixed with 1 ml of random hexamer primer (0.5 mg/ml) and incubated for 10 min at 701C. To each sample was added 4 ml of first strand buffer, 2 ml of 0.1 mol/l dithiothreitol, 1 ml of deoxyribonucleotide triphosphate mix, and 1 ml of Superscript II (Invitrogen, Carlsbad, California USA) and incubated for 1 h at 421C and 15 min at 701C. Fifty nanograms of cDNA were used for PCR amplification; GSTP1 gene expression was determined as described [23] .
Immunoblotting
Cells were divided into two groups. One group was exposed to 1, 5 or 10 mmol/l 5-aza-dC for 72 h, the other was exposed to 20 mmol/l PD98059 for 1 h before adding 10 mmol/l 5-aza-dC and incubating for a further 72 h. Immunoblotting was performed as described previously [24] . Briefly, cells were collected and lysed in cell lysis buffer. After incubation on ice for 30 min and centrifugation (12 000 rpm, 10 min) supernatant total protein content was determined by the Bradford colorimetric method. After denaturation, 50 mg of protein from each sample was separated by 10% SDS-polyacrylamide gel electrophoresis and electroblotted to nitrocellulose. Membranes were blocked with 5% nonfat milk in Trisbuffered saline Tween (TBST) for 2 h at room temperature before overnight incubation at 41C in 5% nonfat milk in TBST containing either tubulin, phosphorylated ERK1/2, ERK1/2, or GSTP1 antibody, followed by 1 h incubation with a peroxidase-conjugated secondary antibody. After extensive washing with TBST, proteins were visualized using an enhanced chemiluminescence reagent (SuperSignal Western Pico Chemiluminescent Substrate; Pierce, Rockford, Illinois, USA).
Detection of GSTP1 hypermethylation by methylation-specific PCR Bisulfite treatment
Genomic DNA was isolated from gastric cancer cells. Sodium bisulfite conversion of 2 mg of genomic DNA was performed by a modification of a previously described method [23] . Briefly, NaOH was added to denature DNA (final concentration, 0.2 mol/l) and incubated for 20 min at 501C. A volume of 500 ml freshly made bisulfite solution (2.5 mol/l sodium metabisulfite and 125 mmol/l hydroquinone, pH 5.0) was added to each sample, incubation was continued at 501C for 3 h in dark. Modified DNA was purified using the Wizard DNA purification resin according to the manufacturer's instructions (Promega) and was eluted with 45 ml of water at 801C. After treatment with NaOH (final concentration, 0.3 mol/l; 10 min, 371C), 75 ml of 7.5 mol/l ammonium acetate was added and incubated for 5 min at room temperature. Finally, modified DNA was precipitated with 2.5 vol 100% ethanol and 2 ml of glycogen (5 mg/ml). The pellet was washed with 70% ethanol, dried, and eluted in 30 ml of 5 mmol/l Tris-HCl pH 8.0.
Methylation-specific PCR analysis
For PCR amplification, 2 ml of bisulfite-modified DNA was incorporated into a final volume of 25 ml of PCR mix containing 1 ml PCR buffer (16.6 mmol/l ammonium sulfate, 67 mmol/l Tris-HCl pH 8.8, 6.7 mmol/l MgCl 2 , 10 mmol/l 2-mercaptoethanol), deoxyribonucleotide triphosphates (each at 1.25 mmol/l), 1 U Platinum Taq DNA polymerase (Life Technologies, Rockville, Maryland, USA) and primers (each 300 ng per reaction). Primer sequences for methylated or modified unmethylated GSTP1 were as described [23] . Methylation-specific PCR was carried out as follows: 1 cycle at 951C for 1 min; 35 cycles of 1 min at 951C, then 1 min at 621C, 1 min at 721C, with final extension for 10 min at 701C. A negative control (water without DNA) was included in each amplification. PCR products (8 ml) from each of the samples were separated on a 2.5% agarose gel, stained with ethidium bromide, and visualized under UV illumination.
Statistical analysis
Data are presented as means ± standard deviations. The significance of the difference between groups was assessed by the w 2 test. A probability value of less than 0.05 was considered significant. All means were calculated from at least three independent experiments.
Results
Sensitivity of human gastric cancer cell lines to different anticancer agents
We used cytotoxicity assays to compare the sensitivity of gastric cancer cell lines MGC803, BGC823, and SGC7901 to different anticancer agents including CDDP, 5-fluorouracil, epirubicin, and paclitaxel. The dose-response curves show that MGC803, BGC823, and SGC7901 cell lines are sensitive to anticancer agents, but the MGC803 cell line was markedly more sensitive to CDDP than the other lines tested (Fig. 1) .
GSTP1 mRNA and protein expression in cell lines MGC803, BGC823, and SGC7901
To determine whether changes in GSTP1 expression might be responsible for the increased CDDP sensitivity of the MGC803 cell line, GSTP1 mRNA and protein expression levels were analyzed. As shown in Fig. 2a , GSTP1 mRNA was readily detected in BGC823 and SGC7901 cells, but was not detectable in MGC803 cells. Protein expression levels largely paralleled the different mRNA levels (Fig. 2b) , demonstrating that GSTP1 enzyme is not expressed significantly in the MGC803 cell line.
DNA hypermethylation and GSTP1 gene expression in human gastric cancer cell lines
To determine whether the lack of GSTP1 expression in the MGC803 cell line might be associated with GSTP1 gene methylation, methylation-specific PCR analysis was used to explore the methylation status of the CpG island located upstream of the GSTP1 transcription start site. Abnormal GSTP1 CpG island hypermethylation was detected in MGC803, but not in BGC823 or SGC7901 (Fig. 3) . To determine whether hypermethylation is associated with GSTP1 transcriptional silencing, MGC803 cells were exposed for 72 h to 5-aza-dC, an inhibitor of DNA methyltransferase. GSTP1 expression was restored after 5-aza-dC treatment (Fig. 4) . These data indicate that CpG island hypermethylation may be responsible for the lack of GSTP1 expression in the MGC803 cell line. We then investigated whether restoration of GSTP1 expression with 5-aza-dC might affect the sensitivity of these cells to different anticancer agents. Figure 5 shows that CDDP cytotoxicity was significantly diminished by 5-aza-dC, whereas the cytotoxicities of the other drugs tested (5-fluorouracil, epirubicin, and paclitaxel) were not affected by 5-aza-dC treatment.
Inhibition of the mitogen-activated protein kinase/ extracellular regulated kinase signaling pathway and GSTP1 expression
We then addressed whether MAPK/ERK signaling also regulates GSTP1 expression in gastric cancer cells. We examined the effects of the selective MAPK/ERK pathway inhibitor PD98059 on GSTP1 expression and drug resistance. PD98059 (20 mmol/l) completely or Methylation status of the glutathione S-transferase-pi (GSTP1) CpG island in gastric cancer cell lines as revealed by methylation-specific PCR. The presence of a strong PCR product in lanes M (93 bp) indicates that the GSTP1 gene is methylated, whereas the product in lanes U (97 bp) indicates that the promoter region is unmethylated. The GSTP1 promoter region is hypermethylated in MGC803, whereas in BGC823 and SGC7901 this remains unmethylated. Water was used as a negative control. M, methylated; U, unmethylated. 5-aza-dC 0 1 5 10
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Glutathione S-transferase-pi (GSTP1) expression in MGC803 cells treated with 5-aza-2 0 -deoxycytidine (5-aza-dC). MGC803 cells were exposed to 5-aza-dC at the indicated concentrations for 72 h. The GSTP1 protein was then detected by western blotting; the arrow indicates the position of the 27 kDa polypeptide. Tubulin provided the loading control.
GSTP1 determines cis-platinum cytotoxicity
partly suppressed the phosphorylation of ERK1/2 in gastric cancer cells. Moreover, PD98059 not only suppressed the upregulation of GSTP1 protein induced by 5-aza-dC in MGC803 (Fig. 6a) , but also suppressed the normal expression of GSTP1 in BGC823 and SGC7901 cells (Fig. 6b) . We then investigated whether MAPK/ERK inhibition might affect the CDDP sensitivity of gastric cancer cells. Cytotoxicity was significantly enhanced in the BGC823 and SGC7901 cell lines. In contrast, MAPK/ERK inhibition did not significantly affect the sensitivity of MGC803 cells that do not express GSTP1 (Fig. 6c) .
Discussion
A significant proportion of gastric cancers fail to respond to platinum-based chemotherapy. The identification of predictive markers has therefore been an important research priority [25, 26] . GSTP1 has emerged as a prognostic marker in human prostate cancer [27] [28] [29] . Expression of GSTP1 can diminish the cytotoxicity of platinum drugs and GSTP1 overexpression has been implicated in resistance to platinum-based chemotherapeutics.
We reported earlier that approximately 70% (91/124) of human gastric cancers ubiquitously express GSTP1, raising the possibility that GSTP1 expression might modulate platinum drug sensitivity in gastric cancer.
We report here that the MGC803 human gastric cancer cell line is significantly more sensitive to CDDP than either the BGC823 or SGC7901 gastric cancer lines. Expression of GSTP1 mRNA and protein was not detected in MGC803 cells, but both GSTP1 transcripts and protein were readily detected in BGC823 and SGC7901. We conclude that MGC803 cells do not express detectable levels of GSTP1. We then examined DNA methylation status in the vicinity of the GSTP1 promoter. In the nonexpressing cell line MGC803, the GSTP1 promoter region was fully methylated. This contrasted with the GSTP1-positive lines BGC823 and SGC7901 where promoter methylation was not detected. Importantly, treatment of MGC803 cells with the demethylating agent 5-aza-dC restored GSTP1 expression. We also report that CDDP cytotoxicity was significantly reduced in the presence of 5-aza-dC. The same result was obtained when CDDP was replaced by oxaliplatin (data not shown). These data suggest that abnormal promoter methylation may play a causative role in downregulating GSTP1 gene expression in MGC803 cells. GSTP1 hypermethylation has been reported in cancers of prostate [30] , liver [31, 32] , breast [33, 34] , and lung [35, 36] .
The MAPK/ERK signaling pathway is vital mediator of cell fates including growth, proliferation, and survival [37] . Constitutively activated ERK signaling has been reported to mediate CDDP resistance in human nonsmall cell lung cancer cells [19, 20] . Activation of ERK signaling is also associated with decreased CDDP sensitivity in ovarian cancer cell lines [21] . No studies have, however, so far addressed the role of MAPK/ERK signaling in gastric cancer cell resistance to CDDP. In this study, treatment of human gastric cancer lines with the selective MAPK/ERK pathway inhibitor PD98059 suppressed ERK1/2 phosphorylation. We report that PD98059 inhibited GSTP1 expression in BGC823 and SGC7901 cells. Importantly, MAPK/ERK inhibition also blocked the upregulation of GSTP1 protein in MGC803 cells brought about by the demethylating agent 5-aza-dC. In the GSTP1-expressing cell lines, BGC823 and SGC7901, CDDP cytotoxicity was also significantly increased by MAPK/ERK inhibition. These data suggest that the MAP/ERK signaling pathway activates GSTP1 expression; inhibition of this pathway with PD98059 leads to downregulation of GSTP1 expression and increased CDDP sensitivity. CDDP and PD98059 may therefore act synergistically; the possibility that a combination of the two drugs could be of utility in a clinical setting deserves attention.
In summary, our data suggest that GSTP1 expression modulates the platinum resistance of gastric cancer cells. GSTP1 gene expression seems to be coordinately regulated by methylation of the gene promoter and by the MAPK/ERK signaling pathway. Evaluation of ERK activity may therefore provide a further marker of utility in predicting which gastric cancers are likely to respond GSTP1 determines cis-platinum cytotoxicity Zhang et al. 213 to platinum therapy. These results extend our understanding of the mechanisms of platinum resistance in gastric cancer and suggest new approaches to reversing platinum resistance.
